期刊
ORAL ONCOLOGY
卷 58, 期 -, 页码 59-70出版社
ELSEVIER SCIENCE BV
DOI: 10.1016/j.oraloncology.2016.05.002
关键词
Immunity; Antigenicity; Immunogenicity; Immunotherapy
资金
- Intramural NIH HHS [ZIA DC000087-01] Funding Source: Medline
- NIDCD NIH HHS [R01 DC000087] Funding Source: Medline
A significant subset of head and neck cancers display a T-cell inflamed phenotype, suggesting that patients with these tumors should respond to therapeutic approaches aimed at strengthening antitumor immune responses. A major barrier to the development of an effective anti-tumor immune response, at baseline or in response to immunotherapy, is the development of an immunosuppressive tumor microenvironment. Several well described mechanisms of effector immune cell suppression in the head and neck cancer microenvironment are discussed here, along with updates on current trials designed to translate what we have learned from pre-clinical and correlative clinical studies into improved responses in patients with head and neck cancer following immune activating therapies. Published by Elsevier Ltd.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据